Literature DB >> 17371973

Delivery of antigen to CD40 induces protective immune responses against tumors.

Karoline W Schjetne1, Agnete B Fredriksen, Bjarne Bogen.   

Abstract

Ligation of CD40 induces maturation of dendritic cells (DC) and could be a useful target for vaccines. In this study, we have constructed two types of Ab-based vaccine constructs that target mouse CD40. One type is a recombinant Ab with V regions specific for CD40 and has defined T cell epitopes inserted into its C region. The other type is a homodimer, each chain of which is composed of a targeting unit (single-chain fragment variable targeting CD40), a dimerization motif, and an antigenic unit. Such proteins bound CD40, stimulated maturation of DC, and enhanced primary and memory T cell responses. When delivered i.m. as naked DNA followed by electroporation, the vaccines induced T cell responses against MHC class II-restricted epitopes, Ab responses, and protection in two tumor models (myeloma and lymphoma). Two factors apparently contributed to these results: 1) agonistic ligation of CD40 and induction of DC maturation, and 2) delivery of Ag to APC and presentation on MHC class II molecules. These results highlight the importance of agonistic targeting of Ag to CD40 for induction of long-lasting and protective immune responses.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17371973     DOI: 10.4049/jimmunol.178.7.4169

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  24 in total

1.  Cross-priming CD8+ T cells by targeting antigens to human dendritic cells through DCIR.

Authors:  Eynav Klechevsky; Anne-Laure Flamar; Yanying Cao; Jean-Philippe Blanck; Maochang Liu; Amy O'Bar; Olivier Agouna-Deciat; Peter Klucar; Luann Thompson-Snipes; Sandra Zurawski; Yoram Reiter; A Karolina Palucka; Gerard Zurawski; Jacques Banchereau
Journal:  Blood       Date:  2010-06-07       Impact factor: 22.113

2.  DNA vaccine that targets hemagglutinin to MHC class II molecules rapidly induces antibody-mediated protection against influenza.

Authors:  Gunnveig Grodeland; Siri Mjaaland; Kenneth H Roux; Agnete Brunsvik Fredriksen; Bjarne Bogen
Journal:  J Immunol       Date:  2013-08-16       Impact factor: 5.422

Review 3.  Antigen cross-presentation: extending recent laboratory findings to therapeutic intervention.

Authors:  T W H Flinsenberg; E B Compeer; J J Boelens; M Boes
Journal:  Clin Exp Immunol       Date:  2011-05-11       Impact factor: 4.330

Review 4.  CD40-targeted adenoviral cancer vaccines: the long and winding road to the clinic.

Authors:  Basav N Hangalapura; Laura Timares; Dinja Oosterhoff; Rik J Scheper; David T Curiel; Tanja D de Gruijl
Journal:  J Gene Med       Date:  2012-06       Impact factor: 4.565

5.  Superiority in Rhesus Macaques of Targeting HIV-1 Env gp140 to CD40 versus LOX-1 in Combination with Replication-Competent NYVAC-KC for Induction of Env-Specific Antibody and T Cell Responses.

Authors:  Gerard Zurawski; Xiaoying Shen; Sandra Zurawski; Georgia D Tomaras; David C Montefiori; Mario Roederer; Guido Ferrari; Christine Lacabaratz; Peter Klucar; Zhiqing Wang; Kathryn E Foulds; Shing-Fen Kao; Xuesong Yu; Alicia Sato; Nicole L Yates; Celia LaBranche; Sherry Stanfield-Oakley; Karen Kibler; Bertram Jacobs; Andres Salazar; Steve Self; William Fulp; Raphael Gottardo; Lindsey Galmin; Deborah Weiss; Anthony Cristillo; Giuseppe Pantaleo; Yves Levy
Journal:  J Virol       Date:  2017-04-13       Impact factor: 5.103

6.  TLR3 agonist and CD40-targeting vaccination induces immune responses and reduces HIV-1 reservoirs.

Authors:  Liang Cheng; Qi Wang; Guangming Li; Riddhima Banga; Jianping Ma; Haisheng Yu; Fumihiko Yasui; Zheng Zhang; Giuseppe Pantaleo; Matthieu Perreau; Sandra Zurawski; Gerard Zurawski; Yves Levy; Lishan Su
Journal:  J Clin Invest       Date:  2018-08-27       Impact factor: 14.808

7.  Targeting concatenated HIV antigens to human CD40 expands a broad repertoire of multifunctional CD4+ and CD8+ T cells.

Authors:  Anne-Laure Flamar; Yaming Xue; Sandra M Zurawski; Monica Montes; Bryan King; Louis Sloan; SangKon Oh; Jacques Banchereau; Yves Levy; Gerard Zurawski
Journal:  AIDS       Date:  2013-08-24       Impact factor: 4.177

8.  A functional TNFRSF5 gene variant is associated with risk of lymphoma.

Authors:  Christine F Skibola; Alexandra Nieters; Paige M Bracci; John D Curry; Luz Agana; Danica R Skibola; Alan Hubbard; Nikolaus Becker; Martyn T Smith; Elizabeth A Holly
Journal:  Blood       Date:  2008-02-20       Impact factor: 22.113

9.  Antigen Targeting to Human HLA Class II Molecules Increases Efficacy of DNA Vaccination.

Authors:  Gunnveig Grodeland; Agnete Brunsvik Fredriksen; Geir Åge Løset; Elisabeth Vikse; Lars Fugger; Bjarne Bogen
Journal:  J Immunol       Date:  2016-09-26       Impact factor: 5.422

Review 10.  Targeting human dendritic cells in situ to improve vaccines.

Authors:  Kartik Sehgal; Kavita M Dhodapkar; Madhav V Dhodapkar
Journal:  Immunol Lett       Date:  2014-07-27       Impact factor: 3.685

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.